Please check your internet connection and try again.
# Walethmade bromide
## Overview
"Walethmade bromide" is not a recognized generic or brand name for a pharmaceutical agent. It appears to be a transcription error or an obscured search term. Commonly confused terms may include **Aclidinium bromide**, **Tiotropium bromide**, or **Umeclidinium bromide** (Long-acting muscarinic antagonists/LAMA). Please verify the spelling or generic identity from the medication container or prescription order.
## Primary Indications
Assuming the intended drug belongs to the LAMA class (e.g., Tiotropium):
* Maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
* Asthma (specific formulations only).
## Adult Dosing
* **Tiotropium (Spiriva HandiHaler):** 18 mcg (one capsule) inhaled once daily.
* **Tiotropium (Spiriva Respimat):** 2.5 mcg/actuation; 5 mcg (two actuations) inhaled once daily.
* **Aclidinium bromide:** 400 mcg inhaled twice daily.
## Pediatric Dosing
* **Tiotropium (Respimat):** FDA approved for asthma in patients aged 6 years and older.
* Age 6–17 years: 2.5 mcg (two actuations) inhaled once daily.
* Other LAMAs lack established pediatric safety data for common maintenance indications.
## Dose Adjustments
* **Renal Impairment:** No initial dosage adjustment required for LAMAs; however, monitor patients with moderate-to-severe renal impairment due to anticholinergic systemic accumulation.
* **Hepatic Impairment:** No dosage adjustment necessary.
## Contraindications
* Hypersensitivity to the specific drug, atropine, or its derivatives.
* Severe hypersensitivity to milk proteins (applies to specific dry powder inhaler formulations).
## Adverse Effects
* **Common:** Xerostomia (dry mouth), pharyngitis, sinusitis, upper respiratory tract infection.
* **Serious:** Paradoxical bronchospasm, acute narrow-angle glaucoma, urinary retention (especially in patients with BPH or bladder neck obstruction).
## Key Drug Interactions
* **Anticholinergics:** Concomitant use with other anticholinergic medications (e.g., ipratropium, oxybutynin) may lead to additive systemic anticholinergic effects.
## Monitoring
* Monitor for paradoxical bronchospasm upon the first dose.
* Assess lung function (FEV1) and baseline COPD symptom scores.
* Monitor for signs of increased intraocular pressure or urinary retention.
## Clinical Pearls
* **Inhalation Technique:** Proper technique is vital. Ensure the patient demonstrates use of the specific inhaler device (HandiHaler vs. Respimat vs. DPI).
* **Rescue Inhalers:** These medications are for **maintenance only** and are not indicated for the relief of acute bronchospasm.
* **Confusion Risk:** Ensure the patient understands the difference between their rescue inhaler (e.g., Albuterol) and their maintenance LAMA.
***
**Educational Disclaimer:** The information provided here is for educational purposes and does not replace professional clinical judgment. Drug identities and dosages must be verified against current official labeling, pharmacy databases, or local hospital protocols before administration. If the drug name provided is correct, search again using the verbatim label from the medication.
